Jump to section
To build foundation models that transform biology.
Founded in 2024, Bioptimus is on a mission to build an AI-powered foundation biology model. The biomedical space is becoming far more open to adopting new technology, and with an extensive pool of knowledge from former Google DeepMind and Owkin scientists, this could be a pivotal time for the company to make a change in the space.
By employing AI models trained on vast biological data, Bioptimus is working to unveil complex laws of biology that have so-far remained indecipherable. This comprehensive, deep understanding will be crucial for accelerating breakthroughs in both biomedicine and environmental science.
The Paris-based company has achieved a significant milestone by securing seed funding, which it is using to scale operations and advance its AI model. The exciting achievement will give the company a chance to showcase its potential to reshape the future of biomedicine and scientific innovation.

Freddie
Company Specialist at Welcome to the Jungle
Jan 2025
$41m
SERIES A
Feb 2024
$35m
SEED
This company has top investors
Rodolphe Jenatton
(Co-Founder & CTO)Previously worked as a Senior Research Scientist at Google, and Senior Machine Learning Scientist at Amazon.
Zelda Mariet
(Co-Founder, Principal Research Scientist & VP of Research)Prior to co-founding Bioptimus in 2023, Zelda was a Senior Research Scientist at Google.
Eric Durand
(Co-Founder)Worked at Owkin as a SVP of Data Science, and spent 7 years at Novartis, most recently as the Director of Data Science.
Felipe Llinares-López
(Co-Founder & VP of AI)Previously a Senior Research Scientist at Google and worked as a Postdoctoral Researcher in Machine Learning and Computational Biology at ETH Zurich.
Jean-Philippe Vert
(Co-Founder & CEO)Also works as the Chief R&D officer at Owkin, and is an Affiliate Professor at Mines Paris. Previously worked for Google as a Senior Staff Research Scientist.